Scientists Unveil a 'Kill Switch' for Cancer Cells

A revolutionary RNA therapy selectively destroys cancer cells by silencing two crucial surface proteins.
The treatment is highly effective across a broad spectrum of cancers—including lung, breast, and prostate—while leaving healthy cells completely unharmed.
This breakthrough approach overcomes cancer's notorious adaptability, creating a powerful new weapon in the fight against the disease.

In a stunning breakthrough presented at the 2025 RNA Therapeutics Conference, scientists from bioAffinity Technologies have revealed a powerful new strategy that forces cancer cells to self-destruct. The discovery targets cancer's insatiable appetite for growth, focusing on two cell surface receptors, CD320 and LRP2, which act as gateways for nutrients like vitamin B12 that fuel runaway cell division [2, 4].

Researchers found that cancer is cunning; blocking just one of these receptors causes the cell to compensate by using the other. But the bioAffinity team discovered the ultimate checkmate: using small interfering RNAs (siRNAs) to silence both receptors simultaneously. This dual-pronged attack doesn't just starve the cell—it flips a mysterious "kill switch," triggering rapid cell death exclusively in cancer cells [4, 6].

“Our studies show that silencing…CD320 and LRP2…selectively kills or halts the growth of cancer cells while leaving normal cells unaffected,” stated Dr. David Elzi, Vice President of Product Development.

This method, now protected by U.S. and Chinese patents, has demonstrated its lethality against lung, breast, prostate, brain, and skin cancer cells, regardless of their mutations [3, 8]. With research already underway for a topical treatment for skin malignancies, this "Achilles' heel" strategy represents a monumental leap toward creating targeted, non-toxic therapies that could redefine cancer treatment for patients worldwide [3, 6].

Scientists Unveil a 'Kill Switch' for Cancer Cells

References

Stay Updated!